Andrew Berk

Andrew is third generation in the Generic Pharmaceutical Industry, both his Father and Grandfather were involved in the Development, Manufacturing, and Sales of some of the very first Generic Pharmaceuticals in the United States. Prior to joining ECI, Andrew was with SST Corp., a 75 year old API Company, where he led In/Out licensing for both API and Finished Dosage. Before joining SST, Andrew was with Ascend Labs from 2004-2014, where he served as Vice President of Business Development, overseeing all aspects of Ascend’s licensing and development portfolio. During his tenure at Ascend the company grew from a zero base of sales to over $100 million dollars, earning the distinction of becoming an IMS ranked “top 10 fastest growing Generic Pharmaceutical company” before Ascend was acquired by Alkem Labs. Andrew received a Bachelor of Science degree from Syracuse University.